Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG

NGR-hTNF

iv q3W or q1W 0.8 mcg/sqm NGR-hTNF

Trial Locations (4)

Istituto Clinico Humanitas, Rozzano

Fondazione San Raffaele del Monte Tabor, Milan

Istituto Europeo Oncologico, Milan

Istituto Nazionale dei Tumori, Milan